These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 27586020)

  • 1. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients.
    Li L; Yi T; Lam CW
    J Pharm Pharm Sci; 2014; 17(4):447-60. PubMed ID: 25579428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity in the Efflux of Glucuronides by Human Transporters: MRP4 Is Highly Active toward 4-Methylumbelliferone and 1-Naphthol Glucuronides, while MRP3 Exhibits Stereoselective Propranolol Glucuronide Transport.
    Järvinen E; Troberg J; Kidron H; Finel M
    Mol Pharm; 2017 Oct; 14(10):3299-3311. PubMed ID: 28850245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
    Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
    Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
    Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
    Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mrp2-related efflux of scutellarin in the intestinal absorption in rats.
    Cao F; Zhang H; Guo J; Ping Q
    Pharmazie; 2008 Jan; 63(1):75-80. PubMed ID: 18271309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
    Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.
    Brand W; Oosterhuis B; Krajcsi P; Barron D; Dionisi F; van Bladeren PJ; Rietjens IM; Williamson G
    Biopharm Drug Dispos; 2011 Dec; 32(9):530-5. PubMed ID: 22083890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
    Tang F; Borchardt RT
    Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
    Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
    Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
    Gedeon C; Behravan J; Koren G; Piquette-Miller M
    Placenta; 2006; 27(11-12):1096-102. PubMed ID: 16460798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
    Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
    Tang F; Borchardt RT
    Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model].
    You HS; Zhang HF; Dong YL; Chen SY; Wang MY; Dong WH; Xing JF
    Zhong Xi Yi Jie He Xue Bao; 2010 Sep; 8(9):863-9. PubMed ID: 20836977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.